文献速递乳腺癌放疗姑息放疗与转移瘤

乳腺癌同期同侧锁骨上淋巴结转移患者锁骨上手术加放疗与单纯放疗的多中心回顾性比较

Comparison of supraclavicular surgery plus radiotherapy versus radiotherapy alone in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis: A multicenter retrospective study.
PubMed 文献 · Radiother Oncol · 2023-03-27

该多中心回顾性研究纳入293例同期同侧锁骨上淋巴结转移乳腺癌患者,85例(29.0%)接受锁骨上淋巴结清扫加放疗,208例(71.0%)接受单纯放疗。两组5年SCRFS、LRRFS、DMFS、DFS和OS均无显著差异,多因素分析显示手术加放疗对任一结局均无显著影响。作者认为患者可能无法从锁骨上淋巴结清扫中获益,远处转移仍是主要失败模式。

要点

  • 锁骨上淋巴结清扫加放疗与单纯放疗相比,5年各生存结局均无显著差异。
  • 多因素分析显示手术加放疗对任一结局均无显著影响。
  • 远处转移仍是主要失败模式,尤其在中危和高危组。

核心结论

  • 同期同侧锁骨上淋巴结转移乳腺癌患者可能无法从锁骨上淋巴结清扫中获益。
  • 远处转移仍是主要失败模式,尤其对中危和高危组。

研究设计与样本

  • 多中心回顾性研究纳入3个中心共293例同期同侧锁骨上淋巴结转移乳腺癌患者。
  • 85例(29.0%)接受锁骨上淋巴结清扫加放疗,208例(71.0%)接受单纯放疗。
  • 所有患者均接受术前全身治疗,随后行乳房切除术或肿物切除术及腋窝清扫。
  • 采用Kaplan-Meier法和多因素Cox模型评估SCRFS、LRRFS、DMFS、DFS和OS,缺失数据采用多重插补。

主要发现

  • 单纯放疗组与手术加放疗组中位随访时间分别为53.7个月和63.5个月。
  • 单纯放疗组 vs 手术加放疗组5年SCRFS为91.7% vs 85.5%(P=0.522)。
  • 单纯放疗组 vs 手术加放疗组5年LRRFS为79.1% vs 73.1%(P=0.412)。
  • 单纯放疗组 vs 手术加放疗组5年DMFS为60.4% vs 58.8%(P=0.708)。
  • 单纯放疗组 vs 手术加放疗组5年DFS为57.6% vs 49.7%(P=0.291),5年OS为71.9% vs 62.2%(P=0.272)。

关键数值与推荐

  • 多因素分析中手术加放疗与单纯放疗相比对任一结局均无显著影响。
  • 基于DFS的4个危险因素将患者分为3个危险组,中危和高危组生存结局显著低于低危组。
  • 手术加放疗与单纯放疗相比未改善任何危险组的结局。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate and compare the outcomes of supraclavicular lymph node dissection plus radiotherapy (RT) and RT alone for patients with synchronous ipsilateral supraclavicular lymph node metastasis. METHODS: In all, 293 patients with synchronous ipsilateral supraclavicular lymph node metastasis across three centers were included. Of these, 85 (29.0%) received supraclavicular lymph node dissection plus RT (Surgery + RT) and 208 (71.0%) received RT alone. All patients received preoperative systemic therapy followed by mastectomy or lumpectomy and axillary dissection. Supraclavicular recurrence-free survival (SCRFS), locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were evaluated by using the Kaplan-Meier method and multivariate Cox models. Multiple imputation was used for missing data. RESULTS: The median follow-up duration of the RT and Surgery + RT groups were 53.7 and 63.5 months, respectively. For the RT and Surgery + RT groups, the 5-year SCRFS rates were 91.7% vs. 85.5% (P = 0.522), LRRFS rates were 79.1% vs. 73.1% (P = 0.412), DMFS rates were 60.4 vs. 58.8% (P = 0.708), DFS rates were 57.6% vs. 49.7% (P = 0.291), and OS rates were 71.9% vs. 62.2% (P = 0.272), respectively. There was no significant effect on any outcome when comparing Surgery + RT versus RT alone in the multivariate analysis. Based on four risk factors of DFS, patients were classified into three risk groups: the intermediate- and high-risk groups had significantly lower survival outcomes than the low-risk group. Surgery + RT did not improve outcomes of any risk group compared with RT alone. CONCLUSIONS: Patients with synchronous ipsilateral supraclavicular lymph node metastasis may not benefit from supraclavicular lymph node dissection. Distant metastasis remained the major failure pattern, especially for intermediate- and high-risk groups.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Song YC, Kong J, Li N, et al. Comparison of supraclavicular surgery plus radiotherapy versus radiotherapy alone in breast cancer patients with synchronous ipsilateral supraclavicular lymph node metastasis: A multicenter retrospective study. Radiother Oncol. 2023. PMID: 36990395. doi:10.1016/j.radonc.2023.109639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。